- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Phase 3
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibRecruitingNCT06997276Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsRecruitingNCT07360314Phase 1
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Study of Multiple Ascending Doses (MAD) of M5542 in Participants With Moderate and Severe EczemaNot yet recruitingNCT07932795Phase 1
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]RecruitingNCT07840287Phase 3
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)RecruitingNCT07176689Phase 4
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Anti-GD2 ADC M3554 in Advanced Solid TumorsRecruitingNCT06641908Phase 1
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)RecruitingNCT07549412Phase 3
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy ParticipantsRecruitingNCT07840612Phase 1
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseRecruitingNCT07332481Phase 3
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)RecruitingNCT07355218Phase 3
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsRecruitingNCT07166601Phase 1
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- SW-682 in Advanced Solid TumorsRecruitingNCT06251310Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)RecruitingNCT07340827Phase 3
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Met Non Small Cell Cancer Registry (MOMENT)RecruitingNCT05376891
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)RecruitingNCT07499362Phase 2
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasNot yet recruitingNCT07850635Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Individual Patient Compassionate Use of MirdametinibAvailableNCT05028166
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Individual Patient Compassionate Use of NirogacestatAvailableNCT05041036
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active, not recruitingNCT06421935Phase 1
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid TumorsCompletedNCT06806046Phase 1
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)CompletedNCT04170153Phase 1
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Effect of Food on Peposertib PKCompletedNCT04702698Phase 1
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)Active, not recruitingNCT05797740
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Phase 1/2
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy ParticipantsSuspendedNCT06577337Phase 1
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Active, not recruitingNCT05540327Phase 2
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasActive, not recruitingNCT03962543Phase 2
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Active, not recruitingNCT05327530Phase 2
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)Active, not recruitingNCT07170644Phase 2
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedNCT06433219Phase 2
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)CompletedNCT05882734Phase 1/2
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)CompletedNCT05396833Phase 1
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Study of M5049 in DM and PM Participants (NEPTUNIA)TerminatedNCT05650567Phase 2
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Nirogacestat in Ovarian Granulosa Cell TumorsCompletedNCT05348356Phase 2
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)CompletedNCT03940703Phase 2
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Mirdametinib + BGB-3245 in Advanced Solid TumorsTerminatedNCT05580770Phase 1/2
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)CompletedNCT03785964Phase 3
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment StudyCompletedNCT06412848
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)Active, not recruitingNCT05464030Phase 1
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedNCT05081180Phase 1
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruitingNCT02864992Phase 2
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)CompletedNCT04941768
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy ParticipantsCompletedNCT07279233Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Evaluate the Effects of Famotidine or Rabeprazole on the PK of NirogacestatCompletedNCT07171619Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- First in Human Study of M6223CompletedNCT04457778Phase 1
Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany
- Effect of Renal Impairment on Enpatoran PharmacokineticsCompletedNCT06589713Phase 1
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male ParticipantsCompletedNCT07259330Phase 1
Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany
- Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)CompletedNCT06308263Phase 1
Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany